Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic and Wegovy contain the same active ingredient—semaglutide—but are marketed for different purposes. While Ozempic targets blood sugar control in diabetes, Wegovy targets weight management in people without diabetes. Understanding how semaglutide actually produces weight loss helps clarify whether it's right for your health goals.

What Semaglutide Is and How It Works

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medication that mimics a natural hormone your body produces after eating. When semaglutide binds to GLP-1 receptors in your brain and digestive system, it slows stomach emptying, increases feelings of fullness, and reduces hunger signals sent to your brain. This multi-system effect is what makes semaglutide different from older weight loss medications that worked through a single pathway.

The medication was first approved by the FDA in 2009 under the brand name Byetta as a once-weekly injection for type 2 diabetes. During clinical trials, researchers noticed that patients taking semaglutide lost weight even when weight loss was not the primary treatment goal. This observation led to Novo Nordisk developing Wegovy, the weight-loss formulation approved in 2021. Both Ozempic and Wegovy use identical semaglutide molecules; the difference lies in dose strength, indication, and marketing.

Clinical Evidence: Semaglutide's Weight Loss Effectiveness

The STEP trials, a series of large randomized controlled studies published between 2021 and 2022, demonstrated semaglutide's weight loss potential in people without diabetes. Participants receiving the highest dose of semaglutide (2.4 mg weekly) lost an average of 15% of their body weight over 68 weeks, compared to only 3% in the placebo group. In the STEP 3 trial, which included participants with a baseline BMI over 30, the semaglutide group achieved average weight loss of 16%, with many individuals losing 20% or more of their starting weight.

Weight loss typically becomes noticeable after 4 to 8 weeks of consistent use, with the most significant results appearing between weeks 12 and 20. The medication works best when combined with lifestyle modifications including reduced calorie intake and increased physical activity. Long-term follow-up data shows that weight loss is largely maintained as long as patients continue treatment, and weight often returns when semaglutide is discontinued.

Semaglutide for Weight Loss vs. Diabetes Management

Ozempic and Wegovy are technically the same drug but serve different patient populations and insurance categories. Ozempic is indicated for type 2 diabetes and is dosed at 0.5 mg to 1 mg weekly, focusing on improving blood sugar control and reducing cardiovascular risk. Wegovy is indicated for chronic weight management in adults with obesity or overweight with weight-related health conditions, and is dosed up to 2.4 mg weekly for maximum weight loss effect.

For patients without diabetes seeking weight loss, Wegovy is the technically correct choice because it has FDA approval for that specific indication. However, off-label use of Ozempic for weight loss is common in clinical practice. PlexusDx provides compounded semaglutide injections that can be dosed flexibly based on individual response and tolerance, allowing your healthcare provider to optimize your treatment without the brand-name markup. Your dose may need to go up as your body adjusts, but your price at PlexusDx remains flat at $149 per month.

PlexusDx Compounded Semaglutide: Access and Personalization

PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade purity and consistency. Unlike brand-name medications that require insurance coverage or cash prices exceeding $900 per month, PlexusDx offers compounded semaglutide injections starting at just $149 per month—regardless of the dose your provider prescribes. The medication is available in all 50 states without a membership fee or insurance requirement, and qualifies for HSA and FSA spending accounts.

For patients wanting to optimize their results, PlexusDx offers the Precision Peptide Genetic Test, a $99 add-on after your first month of treatment. This test examines genetic variants in your GLP-1 receptor, GIPR receptor, FTO, and MC4R genes to reveal how your body's peptide pathways are wired. Understanding your genetic predispositions helps your clinician determine whether semaglutide alone is optimal or whether combination therapy with tirzepatide (which targets additional receptors) might produce better weight loss outcomes for your specific biology.

Side Effects and Safety Considerations

The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhea, and constipation occur in 20% to 45% of users depending on dose and individual sensitivity. These effects are usually mild to moderate and tend to improve after the first few weeks as your body adapts. Taking semaglutide on an empty stomach or with small meals, staying well-hydrated, and avoiding high-fat foods can minimize GI discomfort.

Rare but serious side effects include pancreatitis (inflammation of the pancreas), gallbladder problems, and diabetic retinopathy worsening in people with pre-existing diabetes. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Before starting semaglutide through PlexusDx, discuss your complete medical history, current medications, and any prior adverse reactions with your assigned healthcare provider to ensure safe, personalized dosing.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide actually approved for weight loss by the FDA?

Yes—Wegovy (semaglutide 2.4 mg weekly) is FDA-approved specifically for chronic weight management. Ozempic is approved for type 2 diabetes, though doctors sometimes prescribe it off-label for weight loss. PlexusDx compounded semaglutide is not itself FDA-approved, but is manufactured by licensed 503A compounding pharmacies using FDA-compliant processes and standards.

How much weight can I realistically expect to lose with semaglutide?

In clinical trials, patients lost an average of 15% of body weight over 68 weeks, with some losing 20% or more. Results vary based on starting weight, diet adherence, exercise, genetics, and how long you take the medication. PlexusDx's Precision Peptide Genetic Test can reveal whether your GLP-1 receptor genetics predict a strong or moderate response, helping set realistic expectations.

Why is PlexusDx semaglutide so much cheaper than Wegovy or Ozempic?

PlexusDx uses licensed 503A compounding pharmacies instead of brand-name manufacturers, eliminating marketing, distribution, and brand markups. At $149 per month flat (regardless of dose), compounded semaglutide costs 75% to 85% less than brand names while delivering the same active ingredient. Pricing includes all dose adjustments—your price stays flat even as your dose increases.

What happens to my weight after I stop taking semaglutide?

Studies show that weight typically returns when semaglutide is discontinued, though the return is often gradual if you maintain improved eating and exercise habits. Most patients regain 50% of lost weight within one year after stopping. Semaglutide works best as long-term therapy rather than a short-term fix, which is why affordable, ongoing access through PlexusDx makes sense for sustained results.

Can the Precision Peptide Genetic Test predict if semaglutide will work for me?

The Precision Peptide Genetic Test examines variants in your GLP1R, GIPR, FTO, and MC4R genes across 14 metabolic pathways. Certain genetic profiles predict stronger GLP-1 receptor signaling and better semaglutide response. The test costs $99 as an add-on after your first month and helps your PlexusDx clinician decide whether semaglutide alone or combination therapy will optimize weight loss for your unique genetic wiring.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves